SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?


To: Harold Engstrom who wrote (3673)12/2/2002 1:06:51 PM
From: fred hayes  Read Replies (1) | Respond to of 10345
 
Thanks Harold, I needed that. I've come back from the window (it's only a few feet down, anyway). Anyway, it's not that I don't understand that we're dealing with an unknown cause or that current art can only slow down progress or mitigate symptoms. It's just that this paper really strikes at the validity of the whole approach, and it seems to make some sense. I am not equipped to evaluate the technical issues so I don't know how valid or important it is. But my top holdings are Elan and Biogen, and with both tied to Antegren, this kinda stuff really gets my attention. And I'd really like to think that my risk capital is helping people. This paper makes it sound like Avonex is a cruel hoax. Very depressing.

fred



To: Harold Engstrom who wrote (3673)12/2/2002 1:47:22 PM
From: fred hayes  Read Replies (1) | Respond to of 10345
 
>>IMO, the article is interesting, but does not represent a shift in thinking about current treatment regimens.<<

After further review....

Clearly you are correct. Thanks again for getting me back on track.

fred